A new concept in the pharmacology of neuroprotection
- 107 Downloads
Vasoactive intestinal peptide (VIP), originally discovered in the intestine as a peptide of 28 amino acids, was later found to be a major brain peptide having neuroprotective activities. To exert neuroprotective activity, VIP requires glial cells secreting neuroprotective proteins. Activity-dependent neurotrophic factor (ADNF) is a recently isolated factor secreted by glial cells under the action of VIP. This protein, isolated by sequential chromatographic methods, was named activity-dependent neurotrophic factor since it protected neurons from death associated with blockade of electrical activity. A fourteen-amino-acid fragment of ADNF (ADNF-14) and the more potent, nine-amino-acid derivative (ADNF-9), exhibit activity that surpasses that of the parent protein with regard to potency and a broader range of effective concentration. Furthermore, the peptides exhibit protective activity in Alzheimer’s disease-related systems (e.g., β-amyloid toxicity and apolipoprotein E deficiencies, genes that have been associated with Alzheimer’s disease onset and progression). ADNP is another glial mediator of VIP-associated neuroprotection. NAP, an eight-amino-acid peptide derived from ADNP (sharing structural and functional similarities with ADNF-9), was identified as the most potent neuroprotectant described to-date in an animal model of apolipoprotein E-deficiency (knock-out mice). These femtomolar-acting peptides form a basis for a new concept in pharmacology: femtomolar neuroprotection.
Index EntriesNeuroprotection femtomolar activity-dependent VIP ADNF
Unable to display preview. Download preview PDF.
- Brenneman D. E. and Gozes I. (1996) A femtomolar-acting neuroprotective peptide. J. Clin. Invest. 97, 2299–2307.Google Scholar
- Brenneman D. E., Hill J. M., and Gozes I. (1998a) Vasoactive intestinal peptide in the central nervous system, Chapter 57, in Psychopharmacology on CD ROM (Watson, S. J., ed.), Lippincott Williams & Wilkins, Baltimore, MD.Google Scholar
- Dibbern D. A., Glazner G. W., Gozes I., Brenneman D. E., and Hill J. M. (1997) Inhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor. J. Clin. Invest. 99, 2837–2841.PubMedGoogle Scholar
- Gozes I. and Brenneman D. E. (1996) Activity-dependent neurotrophic factor (ADNF): an extracellular neuroprotective chaperonin? J. Mol. Neurosci. 7, 235–244.Google Scholar
- Gozes I., Bachar M., Bardea A., Davidson A., Rubinraut S., Fridkin M., and Giladi E. (1997b) Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implication for early treatment of Alzheimers disease. J. Neurobiol. 33, 329–342.PubMedCrossRefGoogle Scholar
- Guo Q., Sebastian L., Sopher B. L., Miller M. W., Glazner G. W., Ware C. B., et al. (1999) Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc. Natl. Acad. Sci. USA 96, 4125–4130.PubMedCrossRefGoogle Scholar
- Harmar A. J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J. R., et al. (1998) International Union of Pharmacology XVIII. Nomenclature of receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP). Pharmacol. Rev. 50, 265–270.PubMedGoogle Scholar
- Hashimoto H., Ogawa N., Hagihara N., Yamamoto K., Imanishi K., Nogi H., et al. (1997) Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation. Mol. Pharmacol. 52, 128–135.PubMedGoogle Scholar
- Khan I., Wallin R., Gupta R. S., and Kammer G. M. (1998) Protein kinase A-catalyzed phosphorylation of heat shock protein 60 chaperone regulates its attachment to histone 2B in the T lymphocyte plasma membrane. Proc. Natl. Acad. Sci. USA 95, 10,425–10,430.Google Scholar
- Krieglstein K., Henheik P., Farkas L., Jaszai J., Galter D., Krohn K., and Unsicker K. (1998) Glial cell line-derived neurotrophic factor requires transforming growth factor-beta for exerting its full neurotrophic potential on peripheral and CNS neurons. J. Neurosci. 18, 9822–9834.PubMedGoogle Scholar
- Zamostiano R., Pinhasov A., Bassan M., Perl O., Steingart R. A., Atlas R., et al. (1999) A femtomolaracting neuroprotective peptide induces increased levels of heat shock protein 60 in rat cortical neurons: a potential neuroprotective mechanism. Neurosci. Lett. 264, 9–12.PubMedCrossRefGoogle Scholar